Pharma BD Deal Intelligence
Degron Therapeutics announced collaboration and exclusive license agreement with Takeda to discover novel molecular glue degraders for multiple targets in oncology, neuroscience, and inflammation. Upfront payment plus milestones totaling up to $1.2B, tiered royalties, and an equity investment from Takeda. Degron retains full ownership of its pipeline. Review update (June 2026): the Takeda collaboration remains ongoing with no public milestone disclosure or termination. Degron has independently advanced its platform — lead asset DEG6498, a first-in-class oral HuR molecular glue degrader, entered a Phase 1 first-in-human study in advanced solid tumors (NCT07244835) with first patient dosed in November 2025, and the company closed a $40M Series A extension on May 14, 2026 (>$95M total raised), with two immunology programs targeted for development-candidate selection in 2026.